Introduction
TRAIL or Apo2L, a recently identi®ed member of the TNF family of apoptosis-inducing ligands, is capable of inducing cell death in a wide range of human tumor cells both in vitro and in vivo (Pitti et al., 1996; Thomas and Hersey, 1998) . TRAIL interacts with ®ve distinct receptors: DR4/TRAIL-R1 (Pan et al., 1997a) , DR5/ TRAIL-R2/TRICK-2 (Pan et al., 1997b; Sheridan et al., 1997) , DcR1/TRAIL-R3/TRID/LIT (Pan et al., 1997b; Sheridan et al., 1997) , DcR2/TRAIL-R4 (DegliEsposti et al., 1997) and osteoprotegrin (Emery et al., 1998) . Both DR4 and DR5 are type I transmembrane proteins that contain cytoplasmic death domains and, upon ligation, mediate apoptosis. Neither DcR1 (which is glycophosphatidylinositol linked) nor DcR2 (containing an incomplete cytoplasmic death domain) are able to mediate apoptosis of tumor cells upon ligation with TRAIL (Pan et al., 1997b; Sheridan et al., 1997; Degli-Esposti et al., 1997) .
Since its discovery, TRAIL has been tested on a number of dierent tumor cell lines including those derived from melanomas, hematological malignancies and cancers of the lung, colon, kidney, cervix and breast. Based on these studies, a high proportion of human tumor cells have been shown to be sensitive to TRAIL-mediated apoptosis when treated in vitro (Grith et al., 1998; Snell et al., 1997; Rieger et al., 1998; Zhang et al., 1999) . In addition, Walczak et al. (1999) have recently demonstrated the eectiveness of leucine-zipper TRAIL (LZ-TRAIL) in a mammary adenocarcinoma xenograft model treated in vivo. Treatment of tumor-bearing mice with LZ-TRAIL prolonged survival in the mice (50% survived beyond 70 days and 25% were alive at 90 days) compared with the control group (all mice died by 40 ± 50 days). No systemic toxicity was observed in this investigation, suggesting that TRAIL suppressed tumor growth in vivo without aecting the normal tissues of the mice.
The molecular regulation of TRAIL-induced apoptosis is now known to have many important features in common with that of TNF-and Fas-induced apoptosis, although some critical dierences are also emerging. For example, like FasL, TRAIL can kill many sensitive tumor cells in 4 ± 8 h, but TNF-mediated cell killing requires more than 24 h (Mariani et al., 1997) . Although TNF and FasL are extremely ecient at killing a variety of tumor cells, they also cause signi®cant damage to normal tissues. TRAIL appears to be preferentially cytotoxic to tumor cells although that idea has recently been questioned with speci®c regard to human liver cells (Jo et al., 2000) .
Apoptotic cell death induced by death cytokines involves a rapid biochemical process that is characterized by the activation of the caspase cascade, resulting in the cleavage of numerous intracellular proteins (Woo et al., 1998; Yamada et al., 1999) . TRAIL's engagement of its receptors leads to recruitment of the adaptor molecule FADD, which results in activation of the caspase cascade through activation of caspase-8 (Bodmer et al., 2000) . Bcl-2 and Bcl-x L have been shown to block the apoptotic response to cancer therapeutics such as radiation and chemotherapeutic drugs and protect cells from apoptosis induced by both FasL and TNF (Itoh et al., 1993; Jaattela et al., 1995; Boise and Thompson, 1997) . With regard to the potential use of TRAIL in cancer therapy, we wanted to determine if TRAIL-induced apoptosis was suppressed by bcl-2. The present study was therefore designed to compare the levels of apoptosis induced by recombinant human TRAIL in pairs of isogenic human prostate tumor cell lines that do or do not express bcl-2 and examine caspase activation in these lines.
Results

Induction of apoptosis in human prostate cancer cells
Three human prostate tumor cell lines and their bcl-2-expressing counterpart lines were tested for their susceptibility to TRAIL-induced apoptosis as assessed using a DNA fragmentation assay. The levels of bcl-2 protein expressed in these cell lines is depicted in Figure 1 . Because inhibition of protein synthesis has been shown previously to sensitize cells to apoptosis induced by TRAIL and other cell death inducing ligands (Enari et al., 1995) , cells were exposed to TRAIL in the presence of cycloheximide (CHX). To determine the dose-response relationship, PC3 vectorcontrol cells (PC3 neo) were incubated with increasing concentrations of TRAIL (8 ± 16 ng/ml) for 6 h. Given the near equivalence in apoptosis induction at 8, 12 and 16 ng/ml doses (Figure 2a ), further experiments with this cell line were carried out using 8 ng/ml of TRAIL. The DNA fragmentation assay showed that apoptosis was induced rapidly in PC3 neo-control cells reaching levels of nearly 80% by 6 h (Figure 2b ). Apoptosis levels higher than this could not be measured due to massive destruction of the cells. Dose-response experiments with DU145 neo-control cells (Figure 2c ) and LNCaP neo-control cells (Figure 2d ) showed a somewhat suppressed apoptotic response compared to PC3 cells. In every case, the protein synthesis inhibitor, CHX, was required for apoptosis to occur at these low concentrations of TRAIL, indicating the presence of pathways capable of inhibiting apoptosis in these cells. CHX did not, however, induce apoptosis on its own. Apoptosis in all three bcl-2-expressing counterpart lines was greatly suppressed even in the presence of CHX. This was most apparent in PC3 cells, where bcl-2 expression lowered DNA fragmentation following a 6 h treatment with 8 ng/ml TRAIL from 78.9 ± 0.66%.
Activation of caspases in TRAIL-induced cell death
Activation of the caspase cascade and cleavage of speci®c cellular proteins characterize TNF-and FasLinduced cell death. It has been suggested that many of the molecular pathways involved in apoptosis mediated by these death receptors also participate in TRAILinduced cell death. To determine the kinetics of caspase activation in prostate cancer cells, we exposed PC3-neo and bcl-2-transfected cells to TRAIL plus CHX for dierent durations of time, lysed the cells, and separated cellular proteins by SDS ± PAGE. Western blot analysis of caspase-3, -8, -9 and -10, showed that caspase-3 activation occurred in the PC3 neo control cells within 2 h after treatment with TRAIL, as indicated by the decrease in the levels of procaspase 3 and accumulation of the active caspase 3 fragment. Similarly, activation of caspase-8 was detected in the PC3-neo cells within 2 h after addition of TRAIL (Figure 3 ). Caspase-9 also appeared to be activated in PC3-neo cells based on the decline in the expression of the procaspase form. Bcl-2 expression in the PC3 cells blocked activation of these caspases (Figure 3 ). These results demonstrate the rapid activation of the caspase cascade similar to that seen for other death receptors. Caspase-10, did not appear to be activated in response to TRAIL (Figure 3) .
To determine whether caspase activation was essential for TRAIL-induced cell death, we added the tetrapeptide caspase inhibitors Z-DEVD-FMK, Z-IETD-FMK and Z-LEHD-FMK at 100 mM to PC3-neo and bcl-2-transfected cells 1 h before adding TRAIL and CHX. In the TRAIL-sensitive PC3-neo cells, Z-DEVD-FMK, Z-IETD-FMK and Z-LEHD-FMK each completely blocked the activation of all three caspases as demonstrated by Western blot analysis (Figure 4a) . In experiments to assess apoptosis, PC3-neo cells were treated with 100 mM of either caspase-3, -8 or -9 inhibitor 1 h before the addition of TRAIL and CHX. These inhibitors blocked TRAILinduced cell death in PC3-neo cells as demonstrated by DNA fragmentation (Figure 4b ), suggesting that multiple caspase pathways are involved in TRAILinduced cell death. It has been reported that TRAIL induces cleavage of Bid via activated caspase-8, which is followed by loss of mitochondrial membrane potential, release of cytochrome c, and activation of caspase-3, resulting in apoptosis (Yamada et al., 1999) . To examine the eect of overexpression of bcl-2 on Bid in PC3 cells treated with TRAIL, we performed Western blot analysis using an anti-human Bid antibody (the antibody used did not recognize the cleaved form of Bid). Levels of intact Bid were reduced by 6 h in the PC3 neo-control cells after treatment with TRAIL and CHX ( Figure 5a ) but not in the bcl-2 expressing cells. Levels of full length Bid were maintained in cells treated with caspase 8 inhibitor (100 mM Z-IETD-FMK), suggesting that TRAIL induces cleavage of Bid via activated caspase-8 ( Figure 5a ). We studied the role of the mitochondria in the apoptotic pathway induced by TRAIL by examining the release of cytochrome c into the cytosol. Cytochrome c was released into the cytosol of PC3 neo-control cells after 6 h of treatment with TRAIL and CHX; this did not occur in the bcl-2 expressing cells ( Figure 5b ).
Expression of FLIP
FLICE-inhibitory protein (FLIP) contains two death eector domains and an inactive caspase domain that binds to FADD and caspase-8 and inhibits death receptor-mediated apoptosis by blocking activation of caspase-8 (Irmler et al., 1997) . We examined whether the expression of FLIP was an important determinant of TRAIL-mediated sensitivity by measuring FLIP levels in PC3-neo and bcl-2 overexpressing PC3 cells before and after treatment with CHX. Cells were exposed to CHX (10 mg/ml) for varying time periods Release of cytochrome c from the mitochondria into the cytosol. PC3-neo and bcl-2 cells were treated with TRAIL (8 ng/ml) and CHX (10 mg/ml) for 6 h. Cytosolic extracts were analysed by Western blot analysis using mouse anti-human cytochrome c antibody. Bcl-2 overexpression blocked the release of cytochrome c from the mitochondria into the cytosol Figure 6 ) and continued to decline through to 6 h. However in the bcl-2 overexpressing cells treatment with CHX did not lower the expression levels of FLIP. Indeed, it appeared that the expression of FLIP protein was enhanced in the bcl-2 expressing cells at 5 ± 6 h of CHX treatment.
Inhibition of protein synthesis
We performed metabolic labeling studies to test whether CHX was inhibiting protein synthesis in the neo and the bcl-2 cells. CHX (10 mg/ml) inhibited protein synthesis in the PC3 neo and bcl-2 overexpressing cells by 95% within 2 h (Figure 7 ). This inhibition was sustained in the PC3 neo cells but protein synthesis appeared to recover somewhat in the bcl-2 expressing cells by 5 h.
TRAIL receptor expression in PC3 cells
It was important to assess whether the resistance of bcl-2 expressing cells was due to altered TRAIL receptor expression. Therefore, DR4, DR5, DcR1 and DcR2 expression was analysed in PC3 neo and bcl-2-expressing PC3 cells treated with either TRAIL, CHX or their combination. The basal levels of expression of all four receptors was identical in the two cell lines. DcR1 was not expressed to any appreciable extent in either line. Although DR5 expression appeared to be slightly enhanced in the bcl-2 expressing line following treatment with TRAIL and CHX, this would not explain the resistance to TRAIL seen in this line (Figure 8 ).
Discussion
The present study has demonstrated that the death ligand TRAIL in combination with CHX induces apoptosis in human prostate cancer cells. Thus, in addition to reports concerning a number of other types of tumor cells, the potential ecacy of TRAIL as a therapeutic has been extended to prostate cancer. Two other groups have also recently reported that TRAIL induces apoptosis in prostate cancer cells (Bonavida et al., 1999; Yu et al., 2000) . TRAIL induced various degrees of apoptosis in the three prostate cancer cell lines described in this study. PC3 cells showed the most dramatic eect, as nearly 80% apoptosis was produced within a 6 h incubation with TRAIL plus CHX. However, in the DU145 cells the same treatment produced only about 15% apoptosis. This combination also produced apoptosis in LNCaP cells; however, a 24 h incubation was needed to achieve an apoptotic response of 11%. The basis for these dierences is currently under investigation, but the status of p53 in the indicated lines did not correlate with response to TRAIL because PC3 cells which express mutant p53 have a much greater response to TRAIL than LNCaP, which has wild-type p53 status.
One factor that does appear to have a substantial eect on TRAIL-induced apoptosis is bcl-2 expression. All three prostate cancer lines examined in this study displayed lower levels of apoptosis when bcl-2 was ectopically expressed. Although it is widely accepted that bcl-2 is a survival factor for many cell types (Korsmeyer, 1992) and that overexpression of bcl-2 results in chemoresistance through blocking of apoptosis (Miyashita and Reed, 1993; Tang et al., 1994) , the ability of bcl-2 to protect against apoptosis induced by TRAIL has been examined to a lesser extent. Rieger et al. (1998) have shown that TRAILinduced apoptosis is inhibited by overexpression of bcl-2 in human glioma cells. However, other studies Gazitt, 1999) have shown that bcl-2-transfected 8226 and ARP-1 myeloma cells are equally sensitive to apoptosis induced by TRAIL as compared to their non-bcl-2 expressing counterparts. Reports from two other groups Walczak et al., 2000) indicate that bcl-2 fails to block cytochrome c release after exposure to TRAIL. However, in their study, Walczak et al. (2000) found that overexpression of bcl-2 in Jurkat cells caused a delay in the loss of mitochondrial permeability transition by about 2 ± 4 h, suggesting that TRAILinduced apoptosis is protected by bcl-2 in the early phase but not in the late phase. We have carried out clonogenic survival assays to rule out the possibility that bcl-2 overexpression simply causes a delay in the apoptotic response (data not shown). These assays con®rmed the fact that bcl-2 overexpression blocks TRAIL-induced cell death. One explanation for the discrepancy between our results and those reported by Walczak et al. (2000) and Keogh et al. (2000) could be that the suppressive eects of bcl-2 on TRAIL-induced apoptosis are cell-type speci®c. Our results are similar to those in a recent report where it was shown that bcl-2 blocks TRAIL-induced apoptosis in non-small cell lung cancer cells (Sun et al., 2001) .
It was not immediately clear where in the apoptosis pathway bcl-2 would act to block TRAIL-induced apoptosis. The emerging model from the literature suggests that following engagement of their receptors, death ligands such as FasL and TRAIL activate caspase-8 via adapter proteins such as FADD (Ashkenazi and Dixit, 1998; Bodmer et al., 2000) . Speci®cally, TRAIL induces the activation of caspase-8, which may in turn directly activate caspase-3. Bcl-2 would not be expected to interfere with this mechanism (Schulze-Ostho et al., 1998) . The use of caspase inhibitors and analysis of caspase activation permitted a ®ner analysis of the TRAIL-mediated signaling pathway in prostate cancer cells.
We observed that exposure of PC3-neo cells to TRAIL plus CHX led to the activation of caspase-3 and -8 and presumably caspase-9 within 2 h of addition of TRAIL. Caspase activation and processing were blocked in the bcl-2-transfected cells (Figure 3) . Inhibitors for caspase-3, -8 and -9 blocked the apoptotic response in the PC3 neo cells (Figure 4) , indicating that these caspases are key executioners for TRAIL-mediated cell death. Western blot analysis also suggested that Bid, a bcl-2 family member, was processed in the neo control cells but not in the bcl-2-expressing cells. Bid has been reported to be a substrate for caspase-8 and the p15 cleavage product of Bid is translocated from the cytosol to the mitochondrial membrane, where it mediates release of cytochrome c into the cytosol (Gross et al., 1999) . Bcl-2 and bcl-x have been shown to regulate this mitochondrial-dependent pathway (Slee et al., 2000) . Our analysis of cytochrome c release was consistent with this possibility. Increased levels of cytochrome c were observed in the cytosol of PC3 neo cells following treatment with TRAIL and CHX. Thus, it appears that TRAIL in combination with CHX can activate mitochondrial-dependent as well as mitochondrialindependent pathways for caspase-3 activation resulting in an ampli®ed response (Kuwana et al., 1998) .
With regard to these pathways, Scadi et al. (1998) have proposed the existence of two dierent cell types, type I and type II, related to their response to CD95L-induced cell death. In their original study, they show that, in CD95-mediated apoptosis, caspase-8 activation is upstream of mitochondrial activation in type I cells, i.e. SKW6.4 cells, and downstream of mitochondrial activation in type II cells, i.e. Jurkat cells. In a Jurkat line engineered to express bcl-2 and, thus, resistant to CD95-triggered apoptosis, cytochrome c was not released from the mitochondria and no activation of caspase 8 occurred. Therefore bcl-2 blocked a feedback loop at the level of mitochondria that subsequently results in ampli®ed caspase 8 activation. Scadi et al. (1998) speculate that in type II cells, either an initial, undetectable level of activated caspase 8 is sucient to activate mitochondria triggering this ampli®cation loop or that other unidenti®ed caspases are activated during CD95 mediated apoptosis that participate in the process. Subsequent studies in other laboratories have validated that apoptosis mediated by a variety of agents in addition to CD95L may be mediated by caspase 8 activation downstream of mitochondrial activation and blocked by bcl-2 or other bcl-2 family members at the level of mitochondria (Boesen-de Cock et al., 1999; Engels et al., 2000; Slee et al., 2000; Belka et al., 2000) . Whether distinct type I and type II cells exist in the context of TRAIL-induced apoptosis is unknown. However, in analogy to CD95L, we hypothesize that PC3 cells are similar to type II cells and that expression of bcl-2 interferes with the TRAILinduced death signal at the level of mitochondria. The bcl-2 expressing PC3 line was resistant to TRAIL and CHX induced apoptosis and this correlated with the lack of cytochrome c release from mitochondria and lack of caspase 8 activation. These results are consistent with those of Scadi et al. (1998) for their type II cells.
Bcl-2 blocks TRAIL-induced cell death
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In the present study we also found that addition of CHX sensitizes prostate cancer cells to TRAILmediated apoptosis. A large body of evidence has shown that, as a protein synthesis inhibitor, CHX can potentiate and, in some cases may be necessary for, the apoptotic eects of certain death stimuli (Wallach, 1984; Martin et al., 1990; Tsuchida et al., 1995; Jacobson et al., 1996) . The possible mechanism of action of CHX in this context, however, is not very well documented. The fact that CHX can render these prostate carcinoma cells sensitive to TRAIL suggests that these cells are synthesizing an internal inhibitor of apoptosis. One of the molecules that could be correlated with resistance to apoptosis is FLICEinhibitory protein (FLIP), as FLIP has been shown to inhibit TRAIL-induced cell death (Irmler et al., 1997) . A recent report has analysed the eect of CHX on CD95, TRAIL and TNF induced apoptosis (Fulda et al., 2000) . They found that treatment with CHX sensitized cells to TRAIL and CD95 induced apoptosis through downregulation of FLIP expression. We observed a lowering of FLIP levels in the PC3 neo cells treated with CHX alone (Figure 7) . These results are consistent with the report of Fulda et al. (2000) .
On the other hand, FLIP protein levels in the bcl-2 overexpressing cells treated with CHX did not decrease and appeared to increase slightly at 5 ± 6 h. These observations may be due to two dierent factors. First, the loss of FLIP protein seen in the PC3 neo cells would be due to continued turnover of the protein in the absence of new protein synthesis. The fact that this turnover does not occur in the bcl-2 expressing cells suggests that either the signaling for FLIP protein destruction or the proteolytic degradation of FLIP is repressed by bcl-2. This is not without precedent since the degradation of the anti-apoptotic transcription factor c-fos by the proteosome has been shown to be blocked by bcl-2 (He et al., 1998) . Second, the enhanced levels of FLIP seen in bcl-2 expressing cells treated with CHX for 5 ± 6 h ( Figure 6 ) could be in response to the recovery in protein synthesis seen at this time (Figure 7 ) in the context of an inhibition of FLIP protein turnover.
In conclusion, we have shown that the apoptosisinducing ligand, TRAIL, has signi®cant apoptosisinducing activity against human prostate cancer cells treated in vitro when combined with CHX. This would have important implications for the therapeutic use of TRAIL in prostate cancer if clinically useful agents could mimic this sensitization eect. Our results also indicate that PC3 cells are similar to type II cells with regard to their use of mitochondrial ampli®cation of the signals leading from engagement of the TRAIL receptors to activation of the caspase-mediated execution of apoptosis. Consistent with other reports concerning this pathway, our data indicate that bcl-2 expression inhibits this ampli®cation resulting in a suppressed apoptotic response to TRAIL. This ®nding would also have implications for the clinical use of TRAIL in prostate cancers where bcl-2 is expressed and we are currently examining combinations of TRAIL with drugs that will produce a sensitizing eect sucient to circumvent the apoptosis-inhibitory in¯uence of bcl-2.
Materials and methods
Cells and recombinant human TRAIL
Human prostate cancer cell lines PC3, DU145 and LNCaP were obtained from the American Type Culture Collection (ATCC) and routinely maintained in RPMI 1640 medium supplemented with 10% FBS, 10 000 U/ml of penicillinstreptomycin, 2 mM L-glutamine. Vector control (PC3-neo) and bcl-2-expressing (PC3-bcl-2) counterpart lines were produced by one of the authors (TJ McDonnell) and maintained in selection medium containing G418 (200 mg/ ml). TRAIL was obtained from R&D Systems (Minneapolis, MN, USA). This recombinant bioactive TRAIL is a nondisul®de-linked homotrimer.
Antibodies and caspase inhibitors
Antibodies for caspase-3, -9, -10, cytochrome-c and I-FLICE (FLIP) were obtained from Pharmingen (San Diego, CA, USA). Antibody to caspase-8 recognizing both the procaspase and the cleaved form was obtained from Alexis Biochemicals (San Diego, CA). Antibody to Bcl-2 was obtained from Dako (Carpinteria, CA, USA). Antibody to Bid was obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Antibodies for the death receptors to TRAIL-DR4, DR5, DcR1 and DcR2 were obtained from Immunex (Seattle, WA, USA). Tetrapeptide inhibitors for caspase-3 (Z-DEVD-FMK), caspase-8 (Z-IETD-FMK) and caspase-9 (Z-LEHD-FMK) were obtained from Calbiochem (San Diego, CA). The inhibitors were resuspended in dimethyl sulfoxide (DMSO, Sigma Chemical Co., St. Louis, MO, USA) and added to cells at a ®nal concentration of 100 mM, 1 h before treatment with TRAIL.
DNA fragmentation
The method used for measuring apoptosis-speci®c DNA fragmentation is a modi®cation of a published procedure and is based on the solubility of low molecular weight DNA in solutions of low salt concentration (Sellins and Cohen, 1987) . Brie¯y, cells labeled by 14 C-TdR incorporation for one cycle were treated with TRAIL and CHX for a period of 6 h to induce apoptosis. After treatment, cells were washed with phosphate-buered saline (PBS) and then lysed with 0.5 ml of lysis buer (10 mM Tris, 1 mM EDTA, 0.2% Triton X-100, pH 7.5) on ice for 20 min. The chromatin was pelleted by centrifugation at 14 000 g for 10 min. The supernatant (fragmented DNA) was removed and the chromatin pellet was solubilized in 1 ml of Soluene (Packard, Meriden, CT, USA). Radioactivity was determined using a liquid scintillation counter (Packard Instruments, Downers Grove, IL, USA). DNA fragmentation was expressed as the percentage of radioactivity found in the supernatant fraction compared to the total radioactivity (pellet plus supernatant).
Preparation of cytosolic extracts for detection of cytochrome c
After 6 h of treatment with TRAIL and CHX, cells were harvested and washed with ice cold PBS. Cells were resuspended in 500 ml of buer A (20 mM HEPES-KOH, pH 7.5, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM sodium EDTA, 1 mM sodium EGTA, 1 mM dithiothreitol) containing 250 mM sucrose and a mixture of protease inhibitors (1 mM PMSF, 1% aprotinin, 1 mM leupeptin, 1 mg/ml pepstatin A, and 1 mg/ml chymostatin). The cells were homogenized in the same buer, with a glass Pyrex homogenizer using a type B pestle (40 strokes). Unbroken cells, large plasma membrane pieces, and nuclei were removed by centrifuging the homogenates at 1000 g at 48C for 10 min. The resulting supernatant was subjected to 10 000 g at 48C for 20 min. The pellet fraction (i.e. mitochondria) was discarded whereas the supernatant was used to generate cytosol. The protein concentration of the cytosolic extracts was determined using the Bio-Rad Dc protein assay system (Hercules, CA, USA). Cytochrome c was detected by Western blot analysis.
Western blot analysis
Cells were harvested after treatment, rinsed in ice-cold PBS and lysed in lysis buer containing 50 mM HEPES (pH 7.9), 0.4 M NaCl, 1 mM EDTA, 2 mg/ml leupeptin, 2 mg/ml aprotinin, 5 mg/ml benzamidine, 0.5 mM phenylmethyl-sulfonyl¯uoride (PMSF) and 1% NP-40. The lysed cells were centrifuged at 14 000 r.p.m. to remove any cellular debris. Protein concentrations of the lysates were determined by the Bio-Rad Dc protein assay system (Hercules, CA, USA). Equal amounts of protein were separated by 12% SDS ± PAGE, transferred to Immobilon (Millipore, Bedford, MA, USA) and blocked with 5% nonfat dry milk in Tris Buered Saline-Tween-20 (0.05%, v/v) for 1 h at room temperature. The membrane was incubated with the respective antibody overnight. After washing, the membrane was incubated with an anti-mouse, anti-goat or anti-rabbit horse-radish peroxidase antibody (diluted 1 : 1000; Amersham Pharmacia Biotech, Arlington Heights, IL, USA) for 1 h. Following several washes, the blots were developed by enhanced chemiluminescence (Amersham, Arlington Heights, IL, USA).
Biosynthetic labeling of proteins
Protein synthesis in CHX treated cells was determined by pulse chase labeling of cells with [ 3 H]leucine (Martin et al., 1990) . PC3 neo and bcl-2 overexpressing cells were treated with 10 mg/ml of CHX for times up to 5 h following which they were washed and incubated for 30 min at 378C in leucine-free RPMI 1640 (Life Technologies., Inc., Rockville, MD, USA) supplemented with 5% dialyzed FCS to deplete intracellular leucine. Cells were then pulsed with [ 
